Literature DB >> 25537566

Nonspecific interstitial pneumonia: survival is influenced by the underlying cause.

Hilario Nunes1, Kirsten Schubel2, Diane Piver3, Eline Magois4, Séverine Feuillet5, Yurdagul Uzunhan6, Zohra Carton2, Abdellatif Tazi5, Pierre Levy7, Pierre-Yves Brillet3, Andrew G Nicholson8, Marianne Kambouchner9, Dominique Valeyre6.   

Abstract

Idiopathic, nonspecific interstitial pneumonia (NSIP) is most often associated with various clinical disorders, including connective tissue diseases (CTDs) and chronic hypersensitivity pneumonitis (cHP). Emerging evidence also suggests that "idiopathic" NSIP may be the lung manifestation of undifferentiated CTD (UCTD). However, whether or not NSIP outcome is influenced by the underlying cause remains uncertain. This retrospective study included 127 biopsy-proven NSIP patients (65 women, mean ± sd age 55 ± 12 years). Survivals were estimated using a Kaplan-Meier curve and compared using the log-rank test. Multivariate analyses were based on a Cox model. 15 (11.8%) patients had cHP, 29 (22.8%) had CTD, 32 (25.2%) satisfied the Kinder criteria for UCTD and 51 (40.1%) had idiopathic NSIP. At the end of follow-up (mean ± sd 64 ± 54 months), a difference in survival was observed between aetiological groups (p=0.002). Survival was better for UCTD than for idiopathic NSIP (p=0.020) and similar to that observed for CTD. cHP survival tended to be poorer than that of idiopathic NSIP (p=0.087) and was an independent predictor of mortality (hazard ratio 2.17, 95% CI 1.05-4.47; p=0.035). NSIP outcome is influenced by its cause. cHP exhibits the highest mortality. UCTD does not differ from CTD supporting the concept of autoimmune NSIP, with a prognosis that is better than that of idiopathic NSIP.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25537566     DOI: 10.1183/09031936.00148613

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

Review 1.  Computational lung modelling in respiratory medicine.

Authors:  Sunder Neelakantan; Yi Xin; Donald P Gaver; Maurizio Cereda; Rahim Rizi; Bradford J Smith; Reza Avazmohammadi
Journal:  J R Soc Interface       Date:  2022-06-08       Impact factor: 4.293

2.  Prognostic factors and outcomes in Japanese lung transplant candidates with interstitial lung disease.

Authors:  Kohei Ikezoe; Tomohiro Handa; Kiminobu Tanizawa; Toyofumi F Chen-Yoshikawa; Takeshi Kubo; Akihiro Aoyama; Hideki Motoyama; Kyoko Hijiya; Shinsaku Tokuda; Yoshinari Nakatsuka; Yuko Yamamoto; Ayako Oshima; Shin-Ichi Harashima; Sonoko Nagai; Toyohiro Hirai; Hiroshi Date; Kazuo Chin
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

Review 3.  Fibrotic Hypersensitivity Pneumonitis: Key Issues in Diagnosis and Management.

Authors:  Vasileios Kouranos; Joseph Jacob; Andrew Nicholson; Elizabetta Renzoni
Journal:  J Clin Med       Date:  2017-06-15       Impact factor: 4.241

4.  Systematic review and meta-analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMJ Open       Date:  2019-05-29       Impact factor: 2.692

Review 5.  Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease.

Authors:  So My Koo; Song Yee Kim; Sun Mi Choi; Hyun Kyung Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2019-05-31

6.  Morphological and molecular motifs of fibrosing pulmonary injury patterns.

Authors:  Danny Jonigk; Helge Stark; Peter Braubach; Lavinia Neubert; Hoen-Oh Shin; Nicole Izykowski; Tobias Welte; Sabina Janciauskiene; Gregor Warnecke; Axel Haverich; Mark Kuehnel; Florian Laenger
Journal:  J Pathol Clin Res       Date:  2019-09-25

Review 7.  Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.

Authors:  John N Shumar; Abhimanyu Chandel; Christopher S King
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

8.  Hyperpolarized 129Xe MRI and Spectroscopy of Gas-Exchange Abnormalities in Nonspecific Interstitial Pneumonia.

Authors:  David G Mummy; Elianna A Bier; Ziyi Wang; Jennifer Korzekwinski; Lake Morrison; Christina Barkauskas; H Page McAdams; Robert M Tighe; Bastiaan Driehuys; Joseph G Mammarappallil
Journal:  Radiology       Date:  2021-07-27       Impact factor: 29.146

9.  Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis.

Authors:  Hideaki Yamakawa; Eri Hagiwara; Hideya Kitamura; Yumie Yamanaka; Satoshi Ikeda; Akimasa Sekine; Tomohisa Baba; Shinichiro Iso; Koji Okudela; Tae Iwasawa; Tamiko Takemura; Kazuyoshi Kuwano; Takashi Ogura
Journal:  PLoS One       Date:  2016-08-26       Impact factor: 3.240

10.  Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study.

Authors:  Sang Hoon Lee; Moo Suk Park; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Woo Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Jong Sun Park
Journal:  Respir Res       Date:  2017-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.